|
Market Closed -
NYSE
16:00:03 2026-10-08 EDT
|
5-day change | 1st Jan Change | ||
| 23.83 USD | -2.81% |
|
-5.55% | - |
| 09-22 | Arcus Biosciences, Inc. Announces New Data for Casdatifan as Treatment for Kidney Cancer Across Multiple Lines of Therapy | CI |
| 09-16 | TD Cowen Initiates Arcus Biosciences at Buy | MT |
Company Valuation: Arcus Biosciences, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,843 | 1,497 | 1,430 | 1,363 | 2,948 | 3,034 | - | - |
| Change | - | -47.33% | -4.52% | -4.7% | 116.38% | 2.91% | - | - |
| Enterprise Value (EV) 1 | 2,344 | 488.4 | 670.7 | 384.6 | 2,066 | 2,594 | 2,932 | 2,729 |
| Change | - | -79.16% | 37.34% | -42.66% | 437.29% | 25.52% | 13.05% | -6.93% |
| P/E | 57x | -5.57x | -4.6x | -4.74x | -7.24x | -6.72x | -6.71x | -7.76x |
| PBR | - | 2.29x | 3.12x | 2.83x | 4.73x | 11x | -33.1x | 8.3x |
| PEG | - | 0x | -0.4x | 0.2x | -1.52x | -0.87x | -37.11x | 0.6x |
| Capitalization / Revenue | 7.43x | 13.4x | 12.2x | 5.28x | 11.9x | 38.6x | 59.9x | 18.1x |
| EV / Revenue | 6.12x | 4.36x | 5.73x | 1.49x | 8.37x | 33x | 57.9x | 16.3x |
| EV / EBITDA | 40.3x | -1.78x | -2.02x | -1.28x | -5.5x | -5.85x | -5.98x | -10.3x |
| EV / EBIT | 43.2x | -1.74x | -1.97x | -1.17x | -5.35x | -5.52x | -6.09x | -6.14x |
| EV / FCF | -8.3x | 1.13x | - | -2.19x | -4.27x | -8.35x | -7.66x | -8.91x |
| FCF Yield | -12% | 88.5% | - | -45.8% | -23.4% | -12% | -13.1% | -11.2% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 0.71 | -3.71 | -4.15 | -3.14 | -3.29 | -3.545 | -3.551 | -3.07 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 382.9 | 112 | 117 | 258 | 247 | 78.61 | 50.68 | 167.9 |
| EBITDA 1 | 58.09 | -274 | -332 | -300 | -376 | -443.4 | -490.2 | -264.1 |
| EBIT 1 | 54.25 | -280 | -340 | -330 | -386 | -470.2 | -481.8 | -444.6 |
| Net income 1 | 52.83 | -267 | -307 | -283 | -353 | -446.4 | -442.5 | -384.4 |
| Net Debt 1 | -499.3 | -1,009 | -759 | -978 | -882 | -440.6 | -102.2 | -305.4 |
| Reference price 2 | 40.47 | 20.68 | 19.10 | 14.89 | 23.83 | 23.83 | 23.83 | 23.83 |
| Nbr of stocks (in thousands) | 70,249 | 72,408 | 74,856 | 91,512 | 123,729 | 127,333 | - | - |
| Announcement Date | 2/23/22 | 2/28/23 | 2/21/24 | 2/25/25 | 2/25/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -6.92x | 34.11x | -6.05x | -.--% | 3.12B | |
| 21.73x | 7.76x | 15.59x | 1.37% | 74.68B | |
| 30.5x | 8.78x | 27.34x | 0.04% | 58.7B | |
| 33.66x | 6.05x | 18.11x | 0.96% | 48.36B | |
| -20.81x | 215.3x | -22.29x | -.--% | 43.05B | |
| 33.24x | 3.23x | 13.97x | -.--% | 42.48B | |
| 48.26x | 5.5x | 30.21x | -.--% | 41.39B | |
| 27.77x | 7.89x | 20.51x | 0.41% | 31.29B | |
| -14.93x | 5.54x | -6.96x | -.--% | 23.93B | |
| -61.76x | 11.97x | -60.92x | -.--% | 22.22B | |
| Average | 9.08x | 30.61x | 2.95x | 0.28% | 38.92B | |
| Weighted average by Cap. | 17.14x | 30.25x | 9.33x | 0.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- RCUS Stock
- Valuation Arcus Biosciences, Inc.
Select your edition
All financial news and data tailored to specific country editions
